The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS

Shinichi Kako, Yoshinobu Kanda, Jun Kato, Wataru Yamamoto, Seiko Kato, Makoto Onizuka, Akira Yokota, Raine Tatara, Hiroki Yokoyama, Maki Hagihara, Kensuke Usuki, Moritaka Gotoh, Reiko Watanabe, Nobutaka Kawai, Takayuki Saitoh, Heiwa Kanamori, Satoshi Takahashi, Shinichiro Okamoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The optimal treatment for use as a bridge to allogeneic hematopoietic stem cell transplantation at the decision for transplantation has not been established in patients with myelodysplastic syndrome (MDS). We retrospectively evaluated the clinical outcomes after the decision for transplantation in our patients with MDS or acute myeloid leukemia (AML) secondary to MDS, aged more than 15 years, who underwent transplantation between 2007 and 2012. A total of 124 patients were included. We classified patients into two groups according to the bridge treatment selected at the decision for transplantation: Group 1, supportive care (n = 79), immunosuppressive therapy (n = 7), low-dose chemotherapy (n = 12); Group 2, AML-type induction chemotherapy (ICT: n = 22), azacitidine (Aza: n = 4). The rate of blasts in the bone marrow significantly influenced the treatment selection at the time of decision. There was no significant difference between the two groups in the rate of overall survival (OS) from the decision (73.1% vs 80.4% at 1 year) or from transplantation (59.0% vs 59.2% at 1 year). A significant difference was not observed even after patients were stratified according to either the rate of blasts in the bone marrow at the time of decision or the propensity score. In conclusion, the bridge treatment selected at the decision for transplantation did not affect the outcomes of transplantation in patients with MDS. However, this analysis did not include patients who could not undergo transplantation after the decision, and thus a prospective study is warranted.

Original languageEnglish
Pages (from-to)341-349
Number of pages9
JournalHematological Oncology
Volume35
Issue number3
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Myelodysplastic Syndromes
Transplantation
Therapeutics
Acute Myeloid Leukemia
Bone Marrow
Azacitidine
Propensity Score
Induction Chemotherapy
Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents
Survival Rate
Prospective Studies
Drug Therapy

Keywords

  • allogeneic transplantation
  • bridge treatment
  • chemotherapy
  • myelodysplastic syndrome
  • supportive care

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. / Kako, Shinichi; Kanda, Yoshinobu; Kato, Jun; Yamamoto, Wataru; Kato, Seiko; Onizuka, Makoto; Yokota, Akira; Tatara, Raine; Yokoyama, Hiroki; Hagihara, Maki; Usuki, Kensuke; Gotoh, Moritaka; Watanabe, Reiko; Kawai, Nobutaka; Saitoh, Takayuki; Kanamori, Heiwa; Takahashi, Satoshi; Okamoto, Shinichiro.

In: Hematological Oncology, Vol. 35, No. 3, 01.09.2017, p. 341-349.

Research output: Contribution to journalArticle

Kako, S, Kanda, Y, Kato, J, Yamamoto, W, Kato, S, Onizuka, M, Yokota, A, Tatara, R, Yokoyama, H, Hagihara, M, Usuki, K, Gotoh, M, Watanabe, R, Kawai, N, Saitoh, T, Kanamori, H, Takahashi, S & Okamoto, S 2017, 'The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS', Hematological Oncology, vol. 35, no. 3, pp. 341-349. https://doi.org/10.1002/hon.2276
Kako, Shinichi ; Kanda, Yoshinobu ; Kato, Jun ; Yamamoto, Wataru ; Kato, Seiko ; Onizuka, Makoto ; Yokota, Akira ; Tatara, Raine ; Yokoyama, Hiroki ; Hagihara, Maki ; Usuki, Kensuke ; Gotoh, Moritaka ; Watanabe, Reiko ; Kawai, Nobutaka ; Saitoh, Takayuki ; Kanamori, Heiwa ; Takahashi, Satoshi ; Okamoto, Shinichiro. / The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. In: Hematological Oncology. 2017 ; Vol. 35, No. 3. pp. 341-349.
@article{2549ac2ed1104594a96fdd88c3a9f556,
title = "The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS",
abstract = "The optimal treatment for use as a bridge to allogeneic hematopoietic stem cell transplantation at the decision for transplantation has not been established in patients with myelodysplastic syndrome (MDS). We retrospectively evaluated the clinical outcomes after the decision for transplantation in our patients with MDS or acute myeloid leukemia (AML) secondary to MDS, aged more than 15 years, who underwent transplantation between 2007 and 2012. A total of 124 patients were included. We classified patients into two groups according to the bridge treatment selected at the decision for transplantation: Group 1, supportive care (n = 79), immunosuppressive therapy (n = 7), low-dose chemotherapy (n = 12); Group 2, AML-type induction chemotherapy (ICT: n = 22), azacitidine (Aza: n = 4). The rate of blasts in the bone marrow significantly influenced the treatment selection at the time of decision. There was no significant difference between the two groups in the rate of overall survival (OS) from the decision (73.1{\%} vs 80.4{\%} at 1 year) or from transplantation (59.0{\%} vs 59.2{\%} at 1 year). A significant difference was not observed even after patients were stratified according to either the rate of blasts in the bone marrow at the time of decision or the propensity score. In conclusion, the bridge treatment selected at the decision for transplantation did not affect the outcomes of transplantation in patients with MDS. However, this analysis did not include patients who could not undergo transplantation after the decision, and thus a prospective study is warranted.",
keywords = "allogeneic transplantation, bridge treatment, chemotherapy, myelodysplastic syndrome, supportive care",
author = "Shinichi Kako and Yoshinobu Kanda and Jun Kato and Wataru Yamamoto and Seiko Kato and Makoto Onizuka and Akira Yokota and Raine Tatara and Hiroki Yokoyama and Maki Hagihara and Kensuke Usuki and Moritaka Gotoh and Reiko Watanabe and Nobutaka Kawai and Takayuki Saitoh and Heiwa Kanamori and Satoshi Takahashi and Shinichiro Okamoto",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/hon.2276",
language = "English",
volume = "35",
pages = "341--349",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS

AU - Kako, Shinichi

AU - Kanda, Yoshinobu

AU - Kato, Jun

AU - Yamamoto, Wataru

AU - Kato, Seiko

AU - Onizuka, Makoto

AU - Yokota, Akira

AU - Tatara, Raine

AU - Yokoyama, Hiroki

AU - Hagihara, Maki

AU - Usuki, Kensuke

AU - Gotoh, Moritaka

AU - Watanabe, Reiko

AU - Kawai, Nobutaka

AU - Saitoh, Takayuki

AU - Kanamori, Heiwa

AU - Takahashi, Satoshi

AU - Okamoto, Shinichiro

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The optimal treatment for use as a bridge to allogeneic hematopoietic stem cell transplantation at the decision for transplantation has not been established in patients with myelodysplastic syndrome (MDS). We retrospectively evaluated the clinical outcomes after the decision for transplantation in our patients with MDS or acute myeloid leukemia (AML) secondary to MDS, aged more than 15 years, who underwent transplantation between 2007 and 2012. A total of 124 patients were included. We classified patients into two groups according to the bridge treatment selected at the decision for transplantation: Group 1, supportive care (n = 79), immunosuppressive therapy (n = 7), low-dose chemotherapy (n = 12); Group 2, AML-type induction chemotherapy (ICT: n = 22), azacitidine (Aza: n = 4). The rate of blasts in the bone marrow significantly influenced the treatment selection at the time of decision. There was no significant difference between the two groups in the rate of overall survival (OS) from the decision (73.1% vs 80.4% at 1 year) or from transplantation (59.0% vs 59.2% at 1 year). A significant difference was not observed even after patients were stratified according to either the rate of blasts in the bone marrow at the time of decision or the propensity score. In conclusion, the bridge treatment selected at the decision for transplantation did not affect the outcomes of transplantation in patients with MDS. However, this analysis did not include patients who could not undergo transplantation after the decision, and thus a prospective study is warranted.

AB - The optimal treatment for use as a bridge to allogeneic hematopoietic stem cell transplantation at the decision for transplantation has not been established in patients with myelodysplastic syndrome (MDS). We retrospectively evaluated the clinical outcomes after the decision for transplantation in our patients with MDS or acute myeloid leukemia (AML) secondary to MDS, aged more than 15 years, who underwent transplantation between 2007 and 2012. A total of 124 patients were included. We classified patients into two groups according to the bridge treatment selected at the decision for transplantation: Group 1, supportive care (n = 79), immunosuppressive therapy (n = 7), low-dose chemotherapy (n = 12); Group 2, AML-type induction chemotherapy (ICT: n = 22), azacitidine (Aza: n = 4). The rate of blasts in the bone marrow significantly influenced the treatment selection at the time of decision. There was no significant difference between the two groups in the rate of overall survival (OS) from the decision (73.1% vs 80.4% at 1 year) or from transplantation (59.0% vs 59.2% at 1 year). A significant difference was not observed even after patients were stratified according to either the rate of blasts in the bone marrow at the time of decision or the propensity score. In conclusion, the bridge treatment selected at the decision for transplantation did not affect the outcomes of transplantation in patients with MDS. However, this analysis did not include patients who could not undergo transplantation after the decision, and thus a prospective study is warranted.

KW - allogeneic transplantation

KW - bridge treatment

KW - chemotherapy

KW - myelodysplastic syndrome

KW - supportive care

UR - http://www.scopus.com/inward/record.url?scp=85029362200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029362200&partnerID=8YFLogxK

U2 - 10.1002/hon.2276

DO - 10.1002/hon.2276

M3 - Article

C2 - 26643559

AN - SCOPUS:85029362200

VL - 35

SP - 341

EP - 349

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -